Bp Plc Acquires New Position in Zimmer Biomet Holdings Inc (ZBH)

Share on StockTwits

Bp Plc acquired a new stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 25,500 shares of the medical equipment provider’s stock, valued at approximately $3,352,000.

Other large investors have also added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. raised its stake in Zimmer Biomet by 5,200.0% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,007 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 988 shares during the period. Regent Investment Management LLC bought a new stake in Zimmer Biomet in the second quarter valued at approximately $201,000. Azimuth Capital Management LLC bought a new stake in Zimmer Biomet in the second quarter valued at approximately $201,000. Aries Wealth Management bought a new stake in Zimmer Biomet in the second quarter valued at approximately $202,000. Finally, HighPoint Advisor Group LLC bought a new stake in Zimmer Biomet in the third quarter valued at approximately $202,000. Hedge funds and other institutional investors own 86.28% of the company’s stock.

Several analysts have issued reports on the company. Leerink Swann dropped their price objective on Zimmer Biomet from $146.00 to $141.00 and set an “outperform” rating on the stock in a research note on Monday, October 29th. Jefferies Financial Group dropped their price objective on Zimmer Biomet from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Monday, October 29th. Citigroup dropped their price objective on Zimmer Biomet from $129.00 to $122.00 and set a “neutral” rating on the stock in a research note on Monday, October 29th. Barclays dropped their price objective on Zimmer Biomet from $131.00 to $119.00 and set a “sell” rating on the stock in a research note on Monday, October 29th. Finally, Oppenheimer set a $135.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a research note on Monday, October 29th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Zimmer Biomet has an average rating of “Hold” and an average price target of $133.86.

In related news, CEO Bryan C. Hanson purchased 410 shares of Zimmer Biomet stock in a transaction that occurred on Friday, August 31st. The shares were acquired at an average price of $123.03 per share, with a total value of $50,442.30. Following the completion of the transaction, the chief executive officer now directly owns 25,487 shares of the company’s stock, valued at approximately $3,135,665.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Chad F. Phipps sold 30,100 shares of the stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $132.37, for a total value of $3,984,337.00. The disclosure for this sale can be found here. Corporate insiders own 0.71% of the company’s stock.

Shares of NYSE ZBH opened at $115.04 on Wednesday. The company has a market cap of $23.43 billion, a PE ratio of 14.33, a PEG ratio of 2.33 and a beta of 1.16. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.96 and a current ratio of 1.89. Zimmer Biomet Holdings Inc has a 1-year low of $104.28 and a 1-year high of $134.55.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Friday, October 26th. The medical equipment provider reported $1.63 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.60 by $0.03. The company had revenue of $1.84 billion for the quarter, compared to analyst estimates of $1.84 billion. Zimmer Biomet had a return on equity of 12.88% and a net margin of 22.42%. The firm’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.72 earnings per share. Equities research analysts predict that Zimmer Biomet Holdings Inc will post 7.65 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 31st. Investors of record on Friday, September 28th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date was Thursday, September 27th. Zimmer Biomet’s dividend payout ratio is currently 11.96%.

TRADEMARK VIOLATION WARNING: “Bp Plc Acquires New Position in Zimmer Biomet Holdings Inc (ZBH)” was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://weekherald.com/2018/11/07/bp-plc-acquires-new-position-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: Stock Symbols and CUSIP Explained

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply